While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
TipRanks on MSN
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative skin disease, following the trial’s early ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback